Maria R Baer

14PUBLICATIONS

121CO-AUTHORS

Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)AutoimmunityCardiology (incl. cardiovascular diseases)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (14)

Sort by Publication Date:

|Jun 15, 2026

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

|Jun 02, 2026

Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.

|May 18, 2026

Glutamine-dependent downregulation of FLT3-ITD is a mechanism of FLT3 inhibitor resistance in FLT3-ITD AML in hypoxia.

|Jun 25, 2025

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.

Eric D Eisenmann, Ronan Swords, Ying Huang

|Sep 09, 2024

A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis.

Chenyu Lin, Anand A Patel, Dezheng Huo

|Jan 29, 2024

Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.

Jonelle K Lee, Aditi Chatterjee, Mario Scarpa

Pageof 3

Frequent Collaborators

Vu H Duong

Giovannino Silvestri

Aditi Chatterjee

Farhad Ravandi

Kebede H Begna

Tapan M Kadia

Yin Wang

Ashkan Emadi

Sandrine Niyongere

Linde A Miles

Frequent Collaborators

Vu H Duong

Giovannino Silvestri

Aditi Chatterjee

Farhad Ravandi